Trimeris, Roche settle patent dispute with Novartis over HIV drug

Trimeris and partner Roche announced Monday that it will pay Novartis just over $2.4 million to settle patent litigation related to the HIV drug Fuzeon. Under the agreement, Trimeris and Roche will continue to sell Fuzeon under a license to Novartis, and will pay royalties to Novartis.

Reference Articles
Trimeris settles patent dispute over Fuzeon - (BusinessWeek)
Trimeris relieved of repayment of Fuzeon deferred marketing costs to Roche; settles patent litigation with Novartis - (Stock Markets Review)
Trimeris, Roche settle HIV drug suit with Novartis - (Triangle Business Journal)
Trimeris and Roche reach agreement on Trimeris repayment of deferred marketing expense - (Trimeris)

**Published in "First Word"